Transfer Factor is a biological product resulting from breaking and filtering leukocytes from healthy donors. Its objective is, as its name indicates, to transfer the cellular immunity of donors who already have this immune response to people who do not have the immune response.
Transfer factors are a kind of "chemical photograph" of the viruses, bacteria, fungi and parasites that were in contact with the organism itself or with another, and transmit this information to the cells in charge of fighting the disease in the body. organism where they are introduced.
Leukocyte-extracted transfer factor has been used successfully in the treatment of laryngeal papillomatosis, atopic dermatitis, hyper-gammaglobulinemia E, bronchial asthma, mycosis fungoides, herpes zoster, Hodgkin's lymphoma, polymorphic erythema, and chronic mucocutaneous candidiasis.
These small molecules contain only the essence of the immune message and are elaborated based on various combinations of amino acids. They are not vitamins or minerals or herbs. They are a special blend of amino acids.
In Mexico, the National Polytechnic Institute (IPN) announced in April 2020 that it was developing a protocol to evaluate the effect of treatment with Leukocyte Dialyzable Extract (oral transfer) in patients infected with the SARS-CoV virus -2 with initial symptoms (no more than 72 hours) to avoid complications.
At the time it was reported that the protocol was approved by the Research Ethics Committee of the National School of Biological Sciences (ENCB) -where it is developed- and by the Research Ethics Committees, Research Committee and Biosafety Committee of the Conde de Valenciana Institute of Ophthalmology.
Dr. Sonia Mayra Pérez Tapia, executive director of the Medical and Biotechnological Research, Development and Innovation Unit (UDIMEB) of the ENCB of the IPN, highlighted on that occasion that the clinical protocol of this new product is supported by more than 10 years of cutting-edge pharmaceutical basic research and development work.
However, he said that even though the IPN has developed different research projects that have tested the modulation of the organism's immune response in the treatment of various autoimmune, infectious, chronic-degenerative and respiratory diseases caused by viruses with the product injectable, controlled clinical trials were needed.
Until now there has been no further information regarding this specific treatment.
COVID vaccines may need tweaking for new strains, scientists say
Copyright © 2023 driverlesstechnology.online. All rights reserved.